Study at a glance
What question did the studies ask?
Does vitamin D help people withstand repeated respiratory illness or prolonged stress? Trials included adults with frequent illness, older care residents, community volunteers and young athletes.
What did they find?
Some smaller trials reported lower symptom scores or fewer respiratory events. Larger community trials did not establish a clear overall benefit. In one trial of 107 older care residents, fewer respiratory events occurred alongside more falls. A small athlete study had very few usable symptom questionnaires.
What does this mean?
Symptoms, infection events and recent illness reports are different outcomes. They do not provide one complete measure of immune strength or show which immune process caused a difference.
What are the limits?
The populations, treatment schedules and observation periods differed. One large respiratory paper could not be fully assessed. The evidence does not establish protection against every repeated or prolonged stressor, or a supplement schedule suitable for everyone.
Read the full article below ↓Vitamin D trials provide mixed evidence about resistance to repeated respiratory illness. Some smaller studies in selected populations reported benefits, while larger trials did not establish a clear overall advantage. These outcomes do not measure a single property called immune robustness, and one trial in older residents reported more falls alongside fewer respiratory events. This review examines what the studies can establish about maintaining defence during repeated or prolonged challenges. Read the shorter account, Vitamin D and Immune Robustness During Repeated Respiratory Challenges: Study Summary.
Defining the question before interpreting a result
Immune robustness means maintaining an effective response when challenges recur or continue. It is a broader proposition than having fewer symptoms on a questionnaire. A trial may measure infections, antibiotic use, symptom severity or recent illness at an annual visit. Each outcome is relevant, but none captures every aspect of the immune system’s capacity to withstand stress.
The distinction from recovery also matters. Avoiding an infection and returning to normal function after severe illness are different questions. The broader relationships are introduced in Vitamin D and Systemic Resilience and Vitamin D and Adaptive Capacity. Those physiological concepts do not turn a respiratory trial into evidence about every form of physical, psychological or metabolic stress. The present evidence is strongest for specific respiratory outcomes in particular populations.
Vitamin D3 interventions also differ in daily versus intermittent delivery, comparator treatment and starting blood concentrations. Some trials compared supplementation with placebo; another compared a higher monthly dose with standard vitamin D intake. A null comparison between two exposures is not the same experiment as vitamin D versus none. The following regimens identify research conditions and are not personal treatment instructions.
Recurrent respiratory illness in a selected adult group
Bergman and colleagues randomised 140 adults with frequent respiratory infections or relevant antibody disorders to vitamin D3 at 4,000 international units (IU) daily or placebo for one year. The group was clinically selected rather than representative of all healthy adults. The main outcome combined symptoms and antibiotic use into an infection score. Among the analysed participants, the adjusted score ratio was 0.771, with a 95% confidence interval of 0.604 to 0.985, favouring vitamin D.
This is a positive trial finding, but its meaning depends on the score. Antibiotic use contributed importantly to the difference; the individual symptom components did not all demonstrate benefits. The outcome was not a count of laboratory-confirmed infections, and it cannot establish that a particular pathogen was prevented. A composite score combines clinically relevant experiences but can conceal which component changed.
Attrition, self-reported information, the heterogeneous clinical population and changes in the statistical analysis constrain confidence. The study did not show a corresponding improvement in measured nasal antimicrobial peptides. Therefore, the clinical score cannot be linked confidently to that proposed mechanism. The early defence background in Vitamin D and Innate Immunity is relevant, but the trial did not demonstrate a complete chain from vitamin D to peptide change to infection prevention.
The study remains useful rather than being dismissed because it is small. It supplies evidence of a potential benefit in people with substantial recurrent illness. Its limits concern generalisation and the exact process measured. It cannot establish that the same regimen improves resilience in adults without recurrent infections, nor that every immune component becomes more effective.
Older residents: respiratory benefit and a fall signal
Ginde and colleagues enrolled 107 adults aged at least 60 across 25 long-term-care facilities. The higher-dose group received 100,000 IU vitamin D3 monthly in addition to usual intake. Controls continued their usual 400 to 1,000 IU daily, or received 12,000 IU monthly when usual intake was below 400 IU daily. This was a higher-versus-standard exposure comparison over a year, not vitamin D versus none. It recorded 32 medically attended acute respiratory events in the higher-dose group and 48 in the standard-dose group. The incidence-rate ratio was 0.60, with a 95% confidence interval of 0.38 to 0.94.
These are event counts rather than the numbers of people who ever became ill; a participant could contribute more than one event. The trial did not demonstrate the same benefit for lower respiratory infections or hospitalisation. Recruitment fell short of the planned 200 participants, and the result comes from a specialised residential setting. It should not be described as a definitive answer for all older adults.
The safety result belongs beside the respiratory result. Falls numbered 70 in the higher-dose group and 27 in the standard-dose group, with an incidence-rate ratio of 2.33 (95% confidence interval 1.49 to 3.63). Repeated falls by some participants contributed to the difference, and baseline fall history was not available. The signal does not establish that every vitamin D regimen increases falls, but it prevents a claim of uncomplicated benefit from this intervention.
The population context in Vitamin D in Older Adults helps explain why setting matters. Residential care can involve different exposure patterns, frailty and competing risks from those in community volunteers. A respiratory improvement should not be called improved whole-person robustness without considering the other outcomes. This study illustrates why selecting only the desired immune result would distort the treatment comparison.
DO-HEALTH: a larger trial with a different infection comparison
DO-HEALTH enrolled 2,157 relatively healthy community-dwelling Europeans aged 70 or older. It tested vitamin D3 at 2,000 IU daily, omega-3 fatty acids and a home strength-exercise programme in a factorial design over three years. Participants reported infections quarterly, with physician assessment of available information. This gives a longer observation period than a brief laboratory response study.
Vitamin D did not establish a reduction in infection rate: the adjusted rate ratio was 0.95, with a 99% confidence interval of 0.84 to 1.08 and P=0.33. The 99% interval reflects the study’s approach to multiple primary questions and should not be silently replaced with a narrower confidence convention. The estimate is compatible with a range of effects around a small average difference, rather than proving exact equivalence.
Interactions in the factorial analysis changed the infection model. The relevant comparison used the vitamin-D-only and placebo-only groups, comprising 272 and 270 participants, rather than simply pooling every person assigned vitamin D against every person not assigned it. The full trial enrolment should therefore not be presented as the sample size of that specific contrast.
The cohort was relatively healthy, and background supplementation was permitted within the study’s limits. Infection ascertainment was not perfect. These features restrict generalisation but do not turn a null result into a hidden positive one. Exploratory age-subgroup findings cannot override the main comparison or establish that a different older population would necessarily benefit.
VITAL: prolonged supplementation with brief illness sampling
Camargo and colleagues reported respiratory outcomes from VITAL, which assigned vitamin D3 at 2,000 IU daily or placebo within a larger factorial trial. The parent trial randomised 25,871 participants; 15,804 had baseline vitamin D measurements, and 15,013 provided the relevant one-year respiratory response. Mean age was about 68, and most participants were vitamin-D-replete.
The one-year odds ratio for recent upper respiratory illness was 0.96, with a 95% confidence interval of 0.86 to 1.06. Repeated annual analyses likewise did not establish benefit. This is important contrary evidence against a broad claim that prolonged supplementation reliably improves respiratory defence in a largely replete community population. A small severely deficient subgroup was too imprecise to establish a different conclusion.
The questionnaires asked about recent illness over the preceding few days. They did not continuously record every infection between annual contacts. A null result therefore concerns the sampled outcome, not a complete year-by-year inventory of recurrent infections. Self-report, selection into measured subsets and allowed background supplements further define the interpretation. VITAL’s inflammation and other ancillary papers share the parent trial; they are not independent replications of the respiratory result.
Training stress: a smaller and weaker signal
Jung and colleagues studied young male taekwondo athletes during winter training. Twenty-six were randomised and 25 completed the four-week intervention of 5,000 IU vitamin D3 daily or placebo. Upper respiratory symptom scores favoured supplementation, but usable symptom questionnaires came from only 17 participants, eight in the vitamin D group and nine in the placebo group. That small effective sample is central to judging the result.
The trial did not demonstrate corresponding treatment-by-time benefits in salivary immunoglobulin A or lactoferrin, substances associated with mucosal defence. A correlation formed by pooling measurements does not show that a within-person immune change caused fewer symptoms. The study supplies a tentative observation during a specific training period, not a robust demonstration that supplementation protects against all prolonged stressors.
The distinct mouse sleep-disruption work in Vitamin D3, Sleep Disruption and Stress-Immune-Gut Measurements: Full Study concerns another model and another stress exposure. It should not be added to the athlete study as if both confirmed the same human outcome. Species, stressor, measured response and treatment context all differ. A scientifically useful comparison preserves those differences instead of converting them into one general claim of resilience.
Why the outcome definitions change the answer
| Trial | Main respiratory information used here | Interpretation limit |
|---|---|---|
| Bergman | Composite symptom and antibiotic score over one year | Improvement need not mean fewer confirmed infections |
| Ginde | Medically attended respiratory-event rate | Events can recur in one person; falls also increased |
| DO-HEALTH | Reported and assessed infections over three years | Factorial interaction changed the analysed comparison |
| VITAL | Recent illness sampled in annual questionnaires | Does not capture every intervening episode |
| Jung | Short-term self-reported symptoms during training | Very few usable questionnaires; immune markers did not confirm a mechanism |
These studies should not be reconciled simply by counting positive and negative papers. Their populations, exposures and measurement methods differ. More informative evidence weighs the precision of the estimate, the validity of the outcome and how directly the study answers the reader’s question. A highly selected small trial can suggest benefit without establishing a general rule; a large null trial can constrain that rule without testing every deficient or frail population.
From immune regulation to a claim of robustness
Vitamin D and Immune Modulation describes the adjustment of immune activity. Neither maximum activation nor the lowest inflammatory signal is automatically desirable in every situation. The respiratory trials chiefly assessed clinical experiences, not a complete model of immune regulation. Their findings cannot identify which immune pathway mediated a difference unless that connection was actually measured and supported.
Similarly, Vitamin D and Adaptive Immunity concerns targeted immune responses and memory. Fewer respiratory symptoms during supplementation do not establish stronger antigen-specific memory or improved vaccine responses. Illness may change through several processes, and exposure may differ. Keeping these relationships explicit makes the clinical research useful without assigning it a mechanism it did not demonstrate.
The four core trials are independent programmes: Bergman, Ginde, DO-HEALTH and VITAL. The small athlete trial adds a distinct but weaker stress context. This review does not pool them into a new numerical estimate. The large D-Health respiratory report by Pham and colleagues (2021; DOI 10.1016/S2213-8587(20)30380-6) was identified, but its complete principal paper was unavailable for assessment here; it remains an access limitation, not a fully evaluated confirmation or refutation. Jolliffe and colleagues’ 2025 respiratory meta-analysis (DOI 10.1016/S2213-8587(24)00348-6) helped identify sources, but its unavailable correction content prevents reliance here on its pooled numerical conclusions.
Conclusion
Vitamin D supplementation showed selected respiratory benefits in some smaller trials, including recurrent-illness patients and long-term-care residents. Larger community trials did not establish a clear overall benefit under their particular outcome definitions. The fall signal in the residential trial and the weak mechanistic correspondence in smaller studies are part of the evidence, not secondary details to omit.
The available results do not establish vitamin D supplementation as a general determinant of immune robustness under repeated or prolonged stress. They support narrower questions about particular populations, regimens and respiratory outcomes. Uncertainty about less-studied groups remains uncertainty; it should neither erase the positive trials nor become a promise that everyone with a low blood result will benefit.
Sources
Related reading
Vitamin D3 Supplementation Reduces the Symptoms of Upper Respiratory Tract Infection during Winter Training in Vitamin D-Insufficient Taekwondo Athletes: A Randomized Controlled Trial
This study examined the effects of vitamin D3 supplementation on salivary immune functions and symptoms of URTI in vitamin D-insufficient taekwondo athletes.
Original paper ↗Read more →Vitamin D and Immune Robustness During Repeated Respiratory Challenges: Study Summary
A clear summary of respiratory studies: some small trials found benefits, larger trials were null, and one older-adult trial reported more falls.
Read more →Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data: Full Evidence Review
Individual participant data meta-analysis examining vitamin D exposure and immune robustness under repeated respiratory infection stress.
Read more →Combined Turmeric, Vitamin C, and Vitamin D Ready-to-Drink Supplements Reduce Upper Respiratory Illness Symptoms and Gastrointestinal Discomfort in Elite Male Football Players
Elite football is associated with the increased risk of illness, although targeted supplementation can reduce illness risk.
Original paper ↗Read more →Vitamin D Modulation of the Innate Immune Response to Paediatric Respiratory Pathogens Associated with Acute Lower Respiratory Infections
Vitamin D is an essential component of immune function and childhood deficiency is associated with an increased risk of acute lower respiratory infections (ALRIs).
Original paper ↗Read more →Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction: A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic
To assess the association between vitamin D deficiency and increased morbidity/mortality with COVID-19 respiratory dysfunction.
Original paper ↗Read more →Association of Maternal Gestational Vitamin D Supplementation with Respiratory Health of Young Children
This study aimed to evaluate the association between maternal gestational Vitamin D3 supplementation and early respiratory health in offspring.
Original paper ↗Read more →Association of vitamin D supplementation with respiratory tract infection in infants
In this prospective birth cohort study, we examined whether vitamin D supplementation reduced RTI risk in 2,244 infants completing the follow‐up from birth to 6 months of age.
Original paper ↗Read more →Calcifediol for Use in Treatment of Respiratory Disease
The aim of this narrative revision is to report the current evidence on the role of calcifediol in main respiratory diseases.
Original paper ↗Read more →Chronic diseases, chest computed tomography, and laboratory tests as predictors of severe respiratory failure and death in elderly Brazilian patients hospitalized with COVID-19: a prospective cohort study
The primary risk factors for severe respiratory failure and death in the elderly hospitalized with COVID-19 remain unclear.
Original paper ↗Read more →Efficacy of Vitamin D Supplements in Prevention of Acute Respiratory Infection: A Meta-Analysis for Randomized Controlled Trials
Methods: We investigated these efficacy results by using a meta-analysis of RCTs.
Original paper ↗Read more →Exercise behavior, practice, injury, and symptoms of respiratory tract infection of 502 Brazilian adults during lockdown oscillations in two years (2021 to 2022) of the COVID-19 pandemic
Participants: A total of 502 adults were evaluated during two consecutive years of the COVID-19 pandemic, corresponding to the years 2021 and 2022.
Original paper ↗Read more →Low cord-serum 25-hydroxyvitamin D levels are associated with poor lung function performance and increased respiratory infection in infancy
The aim of this study was to investigate the impact of perinatal vitamin D levels on respiratory function and disease outcome in infancy.
Original paper ↗Read more →Prenatal Vitamin D Supplementation and Child Respiratory Health: A Randomised Controlled Trial
We examined the effect of prenatal vitamin D on childhood wheezing in an interventional study.
Original paper ↗Read more →The association between early-life respiratory infections and childhood asthma: a meta-analytic perspective
The research team examined 51 studies which they categorized into eight different research areas.
Original paper ↗Read more →Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19
In consideration of the role of vitamin D in the immune system, aim of this study was to analyse vitamin D levels in patients with acute respiratory failure due to COVID-19 and to assess any correlations with disease severity and prognosis.
Original paper ↗Read more →Vitamin D Status and Acute Respiratory Infection: Cross Sectional Results from the United States National Health and Nutrition Examination Survey, 2001 to 2006
Overall, 4.8% (95% CI: 4.5 to 5.2) of participants reported an ARI within 30 days before their participation in the national survey.
Original paper ↗Read more →Vitamin D supplementation to patients with frequent respiratory tract infections: a post hoc analysis of a randomized and placebo-controlled trial
The aim of this study was to test the hypothesis that vitamin D supplementation reduces number of respiratory tract infections (RTIs) and prolong the time to the first RTI in adult patients with frequent RTIs.
Original paper ↗Read more →Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial
We randomized 600 students into 4 treatment arms: 1) vitamin D3 and gargling, 2) placebo and gargling, 3) vitamin D3 and no gargling, and 4) placebo and no gargling.
Original paper ↗Read more →Vitamin D, Colds and Respiratory Infections
Could vitamin D mean fewer colds or chest infections?
Read more →Original sources
Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study
Bergman et al. (2012).
Publication details
Bergman et al. (2012). Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. BMJ Open. 2(6):e001663. DOI: 10.1136/bmjopen-2012-001663.
High Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial
Ginde et al. (2017). High Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial.
Publication details
Ginde et al. (2017). High Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial. Journal of the American Geriatrics Society. 65(3):496 to 503. DOI: 10.1111/jgs.14679.
Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial
Published in JAMA. 324(18):1855-1868. DOI: 10.1001/jama (2020).
Publication details
Bischoff-Ferrari et al. (2020). Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial. JAMA. 324(18):1855-1868. DOI: 10.1001/jama.2020.16909.
Effect of Daily Vitamin D Supplementation on Risk of Upper Respiratory Infection in Older Adults: A Randomized Controlled Trial
Camargo et al. (2024).
Publication details
Camargo et al. (2024). Effect of Daily Vitamin D Supplementation on Risk of Upper Respiratory Infection in Older Adults: A Randomized Controlled Trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 78(5):1162 to 1169. DOI: 10.1093/cid/ciad770.
Vitamin D3 Supplementation Reduces the Symptoms of Upper Respiratory Tract Infection during Winter Training in Vitamin D-Insufficient Taekwondo Athletes: A Randomized Controlled Trial
This study examined the effects of vitamin D3 supplementation on salivary immune functions and symptoms of URTI in vitamin D-insufficient taekwondo athletes.
Publication details
Jung et al. (2018). Vitamin D3 Supplementation Reduces the Symptoms of Upper Respiratory Tract Infection during Winter Training in Vitamin D-Insufficient Taekwondo Athletes: A Randomized Controlled Trial. International Journal of Environmental Research and Public Health. 15(9):2003. DOI: 10.3390/ijerph15092003.